Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia.
Treatment of the central nervous system (CNS) is an essential therapeutic component in childhood acute lymphoblastic leukemia (ALL). The goal of this study was to identify molecular signatures distinguishing patients with CNS disease from those without the disease in pediatric patients with ALL. We...
| Publicado en: | Clinical Medicine Insights: Oncology no. 10; pp. 5 - 16 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121030225&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 121030225 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: 2016 iid: 10 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 121030225 121030225 121030225 10.4137/CMO.s18180 121030225 ppf: 5 ppct: 11 formats: fmt: @attributes: type: P tig: atl: Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia. aug: au: Hicks, Chindo Sitthi-Amorn, Jitsuda Douglas, Jessica Ramani, Ritika Miele, Lucio Vijayakumar, Vani Karlson, Cynthia Chipeta, James Megason, Gail affil: Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA sug: subj: Leukemia, Lymphocytic, Acute Central Nervous System Diseases Gene Expression B Lymphocytes Central Nervous System Child Data Analysis Clinical Trials Study Design Probability Reliability Child: 6-12 years ab: Treatment of the central nervous system (CNS) is an essential therapeutic component in childhood acute lymphoblastic leukemia (ALL). The goal of this study was to identify molecular signatures distinguishing patients with CNS disease from those without the disease in pediatric patients with ALL. We analyzed gene expression data from 207 pediatric patients with ALL. Patients without CNS were classified as CNS1, while those with mild and advanced CNS disease were classified as CNS2 and CNS3, respectively. We compared gene expression levels among the three disease classes. We identified gene signatures distinguishing the three disease classes. Pathway analysis revealed molecular networks and biological pathways dysregulated in response to CNS disease involvement. The identified pathways included the ILK, WNT, B-cell receptor, AMPK, ERK5, and JAK signaling pathways. The results demonstrate that transcription profiling could be used to stratify patients to guide therapeutic decision-making in pediatric ALL. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|